Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB707 + Opdualag
- Development stage
- Discontinued
- Lead developer
- Krystal Biotech
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
KB707 + Opdualag is an investigational combination therapy comprising KB707, a genetically modified herpes simplex virus type 1 (HSV-1) designed to deliver interleukin-12 (IL-12) and interleukin-2 (IL-2) directly to the tumor microenvironment, and Opdualag, a fixed-dose combination of the immune checkpoint inhibitors nivolumab (anti-PD-1) and relatlimab (anti-LAG-3). Developed by Krystal Biotech in collaboration with Bristol Myers Squibb, the therapy was evaluated via intratumoral injection for the treatment of unresectable or metastatic melanoma and other advanced solid tumors. The mechanism involves viral-mediated cytokine expression to stimulate local anti-tumor immunity alongside systemic checkpoint blockade to overcome T-cell exhaustion. In August 2025, Krystal Biotech discontinued the development of the injected formulation for solid tumors and melanoma following regulatory shifts in the oncolytic virus landscape.
- Other names
- KB707 + nivolumab + relatlimabKB707 + Opdualag combination
02
Targets
IL-12R (Interleukin-12 receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)LAG3 (Lymphocyte activation Gene-3 protein)PDCD1 (Programmed cell death protein 1 receptor)IL12 (Interleukin-12)IL-2 (Interleukin 2)
Beyond the preview
Go deeper on KB707 + Opdualag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KB707 + Opdualag.